Imagyn divests MAS assets

Brachytherapy provider Imagyn Medical Technologies has agreed to sell its minimal-access surgery (MAS) product lines to Conmed in a stock swap valued at approximately $29.7 million. The sale, which completes the firm's divestiture of its entire MAS product line, will allow the Irvine, CA-based firm to concentrate its efforts on the oncology and critical care markets, said chairman and CEO Charles Laverty.

By AuntMinnie.com staff writers
June 12, 2001

Related Reading

Imagyn buys Intl. Isotopes brachytherapy assets, May 1, 2001

Theragenics adds deal with Imagyn, September 22, 2000

Copyright © 2001 AuntMinnie.com

Page 1 of 181
Next Page